Goldman Sachs Downgrades Amylyx Pharmaceuticals inc. (AMLX) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. SPY
2. EYPT
3. NVDA
4. GNK
5. USO
6. PLUR
7. ARGX
8. AZN
9. SPCX
10. FNGR

Go back to Goldman Sachs Downgrades Amylyx Pharmaceuticals inc. (AMLX) to Neutral

Evercore ISI Downgrades Amylyx Pharmaceuticals inc. (AMLX) to In Line

March 8, 2024 9:27 AM EST

Evercore ISI analyst Umer Raffat downgraded Amylyx Pharmaceuticals inc. (NASDAQ: AMLX) from Outperform to In Line.

The analyst comments "Amylyx failed in their Ph 3 ALS trial today. We thought they had a real shot heading into this study ... not just based on prior... More

Amylyx (AMLX) Falls 70% After Phase 3 PHOENIX Trial of AMX0035 in ALS Did Not Meet Prespecified Primary or Secondary Endpoints

March 8, 2024 7:13 AM EST

Amylyx (NASDAQ: AMLX) Falls 70% After Phase 3 PHOENIX Trial of AMX0035 in ALS Did Not Meet Prespecified Primary or Secondary Endpoints

HOENIX Study Did Not Meet Prespecified Primary or Secondary EndpointsData From 664-Participant Study Reinforce That AMX0035 is Generally Safe and... More

Amylyx Pharmaceuticals (AMLX) Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS

March 8, 2024 7:00 AM EST

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced topline results from PHOENIX, a global, 48-week, randomized, placebo-controlled Phase 3 clinical trial of AMX0035 (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]; RELYVRIO® in the U.S., ALBRIOZA in Canada) in people living with amyotrophic lateral sclerosis (ALS). PHOENIX did not meet its... More

Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $32 at Mizuho

March 8, 2024 6:34 AM EST

Mizuho analyst Graig Suvannavejh raised the price target on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX) to $32.00 (from $27.00) while maintaining a Buy rating.... More